<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428424</url>
  </required_header>
  <id_info>
    <org_study_id>B1801417</org_study_id>
    <nct_id>NCT04428424</nct_id>
  </id_info>
  <brief_title>Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients</brief_title>
  <official_title>The Impact Of RF, And Anti-CCP On RA Patients In Response To Etanercept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      This study is to evaluate available local data in Iraqi patients with rheumatoid arthritis on
      Enbrel treatment with regards to the impact of Rheumatoid factor and Anti-cyclic
      citrullinated peptide using data from the Baghdad Teaching Hospital registry.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change from base line in the Disease Activity Score 28 (DAS28) for patients with moderate to severe RA with positive RF and ACCP treated with etanercept</measure>
    <time_frame>May 2012 until August 2019</time_frame>
    <description>The assessment of efficacy of etanercept in patients with moderate to severe RA with positive RF and ACCP by the change of DAS28 from baseline to the end of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from base line in the Clinical Disease Activity Index (CDAI) for patients with moderate to severe RA with positive RF and ACCP treated with etanercept</measure>
    <time_frame>May 2012 until August 2019</time_frame>
    <description>The assessment of efficacy of etanercept in patients with moderate to severe RA with positive RF and ACCP by the change of CDAI from baseline to the end of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from base line in the Disease Activity Score 28 (DAS28) for patients with moderate to severe RA with negative RF and ACCP treated with etanercept</measure>
    <time_frame>May 2012 until August 2019</time_frame>
    <description>The assessment of efficacy of etanercept in patients with moderate to severe RA with negative RF and ACCP by the change of DAS28 from baseline to the end of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from base line in the Clinical Disease Activity Index (CDAI) for patients with moderate to severe RA with negative RF and ACCP treated with etanercept</measure>
    <time_frame>May 2012 until August 2019</time_frame>
    <description>The assessment of efficacy of etanercept in patients with moderate to severe RA with negative RF and ACCP by the change of CDAI from baseline to the end of the study.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis</arm_group_label>
    <description>Iraqi patients with rheumatoid arthritis that received Enbrel as treatment for disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel</intervention_name>
    <description>As provided in real world practice</description>
    <arm_group_label>Patients with rheumatoid arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients data from the local registry at the Baghdad Teaching Hospital registry.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed RA patients.

             -â‰¥18 years of age

          -  Did not receive previous another biological treatment

        Exclusion Criteria:

          -  Had previous biological treatment

          -  Use of etanercept for less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer</name>
      <address>
        <city>Baghdad</city>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 10, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

